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Abstract
Background: Low-dose aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1) and suppresses platelet
aggregation. It is effective for secondary prevention of cardiovascular events. Because nonsteroidal anti-
inflammatory drugs (NSAIDs) reversibly bind with COX-1, the antiplatelet effects of aspirin may be suppressed
when NSAIDs are co-administered. This interaction could be avoided by avoiding simultaneous administration;
however, the minimum interval that should separate the administration of aspirin and loxoprofen is not well known. In
this study, we investigated how to avoid the influence of NSAIDs on the antiplatelet effects of aspirin. An in vitro
experiment was performed to investigate the influence of ibuprofen and loxoprofen at various concentrations on aspirin’s
antiplatelet action.
Methods: Platelet aggregation and thromboxane B2 (TXB2) levels were measured after addition of aspirin only
and NSAIDs plus aspirin to platelet-rich plasma. NSAIDs were used at their maximum plasma concentrations,
the assumed concentration after 6 h (for loxoprofen only), and the assumed concentration after 12 h of taking one
clinical dose. Platelet aggregation threshold index (PATI), defined as the putative stimulus concentration giving 50%
aggregation, was calculated as an index of aggregation activity.
Results: PATI decreased in ibuprofen plus aspirin group compared to that in the aspirin only group, regardless of
ibuprofen concentration. Furthermore, PATI significantly decreased when aspirin was added after loxoprofen-trans-OH
addition at the maximum concentration (4.1 ± 0.1 μg/mL), compared to that in aspirin only group (5.9 ± 0.1 μg/mL).
PATI showed no significant difference after addition of loxoprofen at the assumed concentration after 6 h (aspirin only
group, 5.0 ± 0.5 μg/mL; loxoprofen-trans-OH plus aspirin group, 4.9 ± 0.4 μg/mL).In addition, TXB2 concentration tended
to decrease with increasing PATI.
Conclusions: It is desirable to avoid ibuprofen co-administration with the usual once-daily low-dose aspirin therapy;
however, a 6-h interval between loxoprofen and aspirin could avoid this potential interaction when loxoprofen is taken
before aspirin.
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Background
Since low-dose aspirin was found to suppress platelet
aggregation [1], several clinical trials have demon-
strated its antiplatelet efficacy [2]. Low-dose aspirin is
widely used for angina pectoris, myocardial infarction,
ischemic cerebro-vascular disease, Kawasaki disease,
and for prevention of thromboembolism after cardiac
surgery. It inhibits cyclooxygenase-1 (COX-1) in the
platelets, suppresses arachidonic acid metabolism, and
prevents the synthesis of thromboxane A2 (TXA2), a
compound that induces platelet aggregation [3]. As-
pirin is considered to suppress platelet aggregation by
acetylating platelet COX-1 in portal immediately after
taking the medication [4]. Aspirin acts on the internal
COX-1 and irreversibly acetylates Ser529 [3]. Access
to COX-1 active site, responsible for TXA2 synthesis,
is then impeded for the lifetime of the platelet. When
COX-1 in the platelets is acetylated by aspirin, the
antiplatelet effects of aspirin are suggested to depend
on platelet turnover and to be maintained until new
platelets, unacetylated by aspirin, are produced [5].
Nonsteroidal anti-inflammatory drugs (NSAIDs), in-
cluding ibuprofen and loxoprofen, are widely used as an-
algesics, antipyretics, and anti-inflammatory agents [6].
NSAIDs also inhibit the access to COX-1 active site for
TXA2 synthesis; however, the mechanism of inhibition
involves formation of a salt bridge with Arg120 of COX-1,
unlike aspirin [7]. Suppression of the platelet function by
NSAIDs is limited to a fixed period after their administra-
tion, because COX-1 inhibition is reversible [8].
Some patients with cardiovascular disorders using low-
dose aspirin simultaneously take NSAIDs for relief of pain
resulting from conditions, such as rheumatoid arthritis
[9]. The antiplatelet effects of aspirin may be decreased
due to co-administration of ibuprofen [3, 10, 11], and a
warning is included in the package inserts of both aspirin
and ibuprofen. When ibuprofen binds with COX-1, it hin-
ders acetylation of the serine residue by aspirin [3]. There-
fore, aspirin needs to bind with COX-1 before ibuprofen
administration to avoid this interaction. It has been re-
ported that the reduction of the antiplatelet effects of as-
pirin was avoided by taking aspirin 2 h before ibuprofen
administration [3]. Although this dosage regimen is only
useful in case of single daily dose of aspirin and ibuprofen,
it is considered that the antiplatelet effects of daily low-
dose aspirin (once a day) are competitively inhibited by
the prolonged use of multiple daily doses of ibuprofen
(three times a day), even when aspirin was taken before
ibuprofen administration [3, 10, 11]. COX-1 inhibition
seems to persist when aspirin is taken on the next day, in
spite of the 12-h period since the last dose of ibuprofen.
Loxoprofen sodium is more frequently prescribed than
ibuprofen in Japan [9, 12]. The antiplatelet effects of as-
pirin were found to be suppressed by loxoprofen;
however, we previously reported that this interaction
might be avoided by taking aspirin 2 h before loxoprofen
in continuous dosing [13]. In other words, this inter-
action might be avoided by taking aspirin 12 h after lox-
oprofen administration.
Some patients take NSAIDs irregularly in case of pain
and self-adjustment. Thus, it seems to be difficult to se-
cure 12 h to avoid this interaction. The minimum time
interval that should separate the administration of as-
pirin and loxoprofen to avoid their interaction is not
well known. In addition, there are two forms of aspirin
tablets, uncoated and enteric-coated tablets. Enteric-
coated aspirin tablets result in a slower inhibitory effect
on platelet COX-1 than the uncoated aspirin tablets
[14]. Therefore, NSAIDs might have different effects de-
pending on the dosage form of aspirin.
We previously reported that the antiplatelet effect of
aspirin was inhibited by ibuprofen but not the other five
NSAIDs investigated in an in vitro experimental study
[15]. In this report, the final concentrations of the
NSAIDs were their maximum plasma concentrations
(Cmax) obtained after one clinical dose. We considered
that the antiplatelet effect of the NSAIDs might appar-
ently conceal their interaction with aspirin. The extent
to which the antiplatelet effect of aspirin was affected
was thought to be depended on the COX-1 inhibitory
activity of each NSAID.
In this study, we investigated that the time interval re-
quired to avoid the influence of NSAIDs on the anti-
platelet effects of aspirin. An in vitro experiment was
performed, in which aspirin and NSAIDs were added to
human blank blood, to investigate the influence of
NSAIDs at various concentrations on the antiplatelet ac-
tion of aspirin. The fluctuation of the serum drug con-
centration with time was considered. We washed the
platelet to avoid the antiplatelet effect of the NSAIDs,
which apparently could affect their interaction with
aspirin.Two NSAIDs, ibuprofen and loxoprofen, were
used. Some information is known about the interaction
of ibuprofen with aspirin; however, only limited informa-
tion is known in case of loxoprofen. Moreover, we inves-
tigated the best timing for taking aspirin, in case of both
uncoated and enteric-coated tablets, and NSAIDs to




Aspirin (Lot. No. TSH5399), ibuprofen (Lot. No.
TSG6469 and KWF6951) were obtained from Wako Pure
Chemical Industries (Osaka, Japan). Loxoprofen-trans-
OH (a mixture of four isoforms of trans-OH loxoprofen
metabolites, Lot. No. L-0179-046-T) was kindly provided
by Daiichi Sankyo Company (Tokyo, Japan). HEPES (Lot.
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No. EX146, EQ115, CW082, and DB223) was obtained
from Dojindo Laboratories (Kumamoto, Japan). Dimethyl
sulfoxide (DMSO, Lot. No. 911 W1022 and 107 N1039)
was obtained from Kanto Chemical Industries (Tokyo,
Japan). Human plasma albumin (Lot. No. M9G6056 and
M2M2762) was obtained from Nacalai tesque (Kyoto,
Japan). Collagen (Lot. No. C003, 0538, 0540, and
0543), as a platelet aggregation stimulus, was obtained
from Arkray (Kyoto, Japan). All other chemicals were
of analytical grade.
Blood collection
Blood samples were collected from healthy adult volun-
teers, including both men and women (n = 6, however
n = 5 for groups added the concentration after 12 h of
taking one clinical dose). Inclusion criteria were non-
smokers, not taking aspirin within 2 weeks or other
medications (containing NSAIDs) within 1 week before
blood collection, and avoiding alcohol, fatty meals, and
large amounts of spinach, garlic, Chinese chive, and
onion after the evening meal on the day before blood
collection because they may affect platelet aggregation
activity [16, 17]. About 20 mL of blood was collected
using a 21G needle into a plastic syringe containing
2 mL of acid-citrate-dextrose (ACD)-A solution. The
blood was divided into plastic tubes containing 5 mL
each and centrifuged at 200 g for 10 min at 25 °C. Platelet
rich plasma (PRP) was obtained from the supernatant of
the blood. Study protocols were approved by the ethics
committee for human material analysis study of the Tokyo
University of Science (approval number 10001, 13002).
Addition of drugs to platelets
Aspirin, ibuprofen and loxoprofen-trans-OH were sus-
pended in a little volume of DMSO, diluted with saline
containing 0.1% human plasma albumin and 1% DMSO
(0.1% Alb) [18]. The final concentration of aspirin was
17 μM, which was enough to induce antiplatelet effects
in the in vitro experimental protocol that adding drugs
to PRP. When the final concentration of aspirin was
lower than 17 μM, the PATI values were not steady. In
contrast, when the final concentration of aspirin was
much higher than 17 μM, platelet aggregation was
hardly induced by the highest concentration of colla-
gen (10 μg/mL). Therefore, it was impossible to
measure the PATI values. The final concentrations of
NSAIDs (ibuprofen and loxoprofen-trans-OH) were
their Cmax, the concentration after 6 h (for loxoprofen
only), and the concentration after 12 h of taking one
clinical dose (ibuprofen, 200 mg; loxoprofen, 60 mg,
Table 1) [19, 20]. The concentration of NSAIDs after
12 h is assumed to be equal to that before taking as-
pirin (at 7:00 in the next morning) in a dosage regi-
men involving NSAID administration 3 times a day
(at 9:00, 13:00, and 19:00). A control, aspirin only,
and NSAID plus aspirin groups were studied for each
NSAID. In NSAID plus aspirin group, aspirin was
added to PRP 6 min after NSAID addition. Each fluid
volume was 1 mL (PRP), 111 μL (NSAID solution),
and 123 μL (aspirin solution). In aspirin only group,
0.1%Alb was added instead of the NSAID while in
the control group, 0.1%Alb was added instead of as-
pirin and NSAID. Because platelet COX-1 was inhib-
ited by aspirin or NSAIDs within 5 min [21] in an in
vitro experimental study and platelet aggregation rate
may be fluctuant if the elapsed time after aspirin
addition was not constant; therefore, preparation of
washed platelets started 6 min after aspirin addition.
Measurement of platelet aggregation
Plt-HEPES solution containing 1 mM MgCl2, 20 mM
HEPES, 0.13 M NaCl, 2 mM KCl, and 0.4 mM NaH2PO4
was prepared. Then, the PRP-drug solution mixture with
added buffer (Plt-HEPES solution: ACD-A solution = 9:
1) was centrifuged at 25 °C, 520 g for 10 min, and the
obtained platelet pellets were re-suspended in Plt-
HEPES solution and CaCl2 solution was added (final
concentration of CaCl2 was 2 mM).
Platelet aggregation was measured using a light trans-
mission aggregometer, PRP313M (IMI Co., Ltd., Saitama,
Japan), according to the Born and Cross method [22].
One-hundred microliters of platelet suspension were
pre-incubated in a cuvette at 37 °C for 3 min in the
PRP313M. Platelet aggregation was measured using col-
lagen as a stimulus for 5 min. The final concentrations
of collagen in the platelet suspension were 0.5, 2, 5, and
Table 1 Concentration of each drug in the additional experiment
Drug Concentration (μM)
Aspirin 17
Ibuprofen (maximum plasma concentration after taking ibuprofen 200 mg) 80.5 [19]
Ibuprofen (assumed concentration after 12 h of taking ibuprofen 200 mg) 2 [19]a
Loxoprofen-trans-OH (maximum plasma concentration after taking loxoprofen 60 mg) 3.4 [20]
Loxoprofen-trans-OH (assumed concentration after 6 h of taking loxoprofen 60 mg) 0.16 [20]
Loxoprofen-trans-OH (assumed concentration after 12 h of taking loxoprofen 60 mg) 0.0046 [20]
aConcentration was simulated using a 1-compartment model
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10 μg/mL. Assuming the light transmission through the
buffer to be 100%, that of the platelet suspension repre-
sented the platelet aggregation rate. Platelet aggregation
was measured within 1 to 2 h after blood collection be-
cause the platelet aggregability was stable during this
period [23].
Data analysis
1) Platelet aggregation rate
The maximum aggregation rates induced by collagen at
the four concentrations used were connected as a grad-
ing curve. The maximum aggregation rate induced by
the highest concentration of collagen (10 μg/mL) was
defined as 100% of platelet suspension, and the putative
agonist-concentration giving 50% aggregation was calcu-
lated and defined as platelet aggregation threshold index
(PATI, Fig. 1) [24]. Therefore, the increase in PATI
means that the platelet aggregation activity was inhibited
because a higher concentration of the stimulus was
needed to induce platelet aggregation. The PATI values
represent the mean ± SEM.
Besides, there are inter-individual and intra-individual
differences in the platelet aggregation activity [25], thus
we also measured platelet aggregation in a drug-free group
(0.1% Alb) as a control in each additional condition.
2) Measurement of thromboxane B2 (TXB2) level in platelet
suspension
Platelet COX-1 activity was determined by measuring
serum levels of TXB2, the major stable metabolite of
TXA2. TXB2 level in platelet suspension was determined
using enzyme-linked immunosorbent assay (Thromb-
oxane B2 EIA Kit, Cayman Co., Ann Arbor, Michigan,
USA). To measure TXB2 derived from platelet COX-1,
TXB2 concentration in the supernatant of the collagen-
stimulated platelet suspension was determined [26].
Platelet suspension was stimulated with 2 or 5 μg/mL
collagen for 5 min, followed by centrifugation at 4 °C,
2000 g for 15 min to remove platelets. Supernatants were
stored at −30 °C until analysis.
3) Statistical analysis
Tukey’s test was used to compare PATI and TXB2 con-
centrations in platelet suspension in each condition. P
value < 0.05 is considered statistically significant.
Results
Added NSAIDs: ibuprofen
The PATI values of the control and ibuprofen (Cmax)
plus aspirin groups were 3.0 ± 0.3 and 3.7 ± 0.3 μg/mL,
respectively. These values were lower than that of the as-
pirin only group (5.5 ± 0.3 μg/mL, Fig. 2a). TXB2 con-
centrations in platelet suspension of the control, aspirin
only, and ibuprofen (Cmax) plus aspirin groups were
1400 ± 300, 200 ± 30, and 930 ± 290 ng/mL, respectively,
which decreased with increasing PATI (Fig. 3a). When
ibuprofen was used at the assumed concentration after
12 h of taking one clinical dose, PATI of the control, as-
pirin only and ibuprofen plus aspirin groups were 1.6 ±
0.5, 5.1 ± 0.6, and 2.6 ± 0.5 μg/mL, respectively (Fig. 2b).
TXB2 concentrations in platelet suspension of the con-
trol, aspirin only and ibuprofen plus aspirin groups were
580 ± 150, 85 ± 19, and 650 ± 170 ng/mL, respectively,
which decreased with increasing PATI (Fig. 3b). PATI in
the ibuprofen plus aspirin group was lower than that in
the aspirin only group, regardless of the concentration
of ibuprofen. Additionally, the PATI values and TXB2
concentrations of the platelet suspension of the group
treated with ibuprofen only were nearly equal to those
of each control group, regardless of their concentrations
(data not shown).
Added NSAIDs: loxoprofen-trans-OH
The PATI values of the aspirin only and loxoprofen-
trans-OH (Cmax) plus aspirin groups were 5.9 ± 0.1 and
4.1 ± 0.1 μg/mL, respectively. These values were higher
Fig. 1 Calculation method of platelet aggregation threshold index (PATI [24]). Light transmission curves were obtained from four experiments
(collagen concentration, A: 0.5, B: 2, C: 5, and D: 10 μg/mL)
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than that of the control (3.3 ± 0.1 μg/mL, Fig. 4a). PATI
of the loxoprofen-trans-OH (Cmax) plus aspirin group
was significantly decreased compared to that of the
aspirin only group. TXB2 concentrations in platelet sus-
pension of the control, aspirin only, and loxoprofen-
trans-OH (Cmax) plus aspirin groups were 1200 ± 700,
190 ± 120, 1100 ± 700 ng/mL, respectively (Fig. 5a). Each
data showed that TXB2 concentrations decreased with
increasing PATI; however, two of the six subjects showed
scores that were several times higher than the TXB2
concentrations of the others. When loxoprofen was used
at the assumed concentration after 6 h of taking a clin-
ical dose of loxoprofen sodium, PATI of the aspirin only
and loxoprofen-trans-OH plus aspirin groups were 5.0 ±
0.5 and 4.9 ± 0.4 μg/mL, respectively. These values were
higher than that of the control (2.7 ± 0.3 μg/mL, Fig. 4b).
In addition, TXB2 concentrations in the aspirin only and
loxoprofen-trans-OH plus aspirin groups were 26 ± 10
and 33 ± 12 ng/mL, respectively, which was lower than
that of the control (260 ± 120 ng/mL, Fig. 5b). PATI and
TXB2 concentrations in platelet suspension showed no
significant differences between the aspirin only and
loxoprofen-trans-OH plus aspirin groups. Similar results
were obtained when loxoprofen was used at the assumed
concentration after 12 h of taking a clinical dose of loxo-
profen sodium (Figs. 4c and 5c). Additionally, the PATI
values and TXB2 concentrations of the platelet suspen-
sion of loxoprofen-trans-OH only groups were nearly
equal to those of each control group, regardless of their
concentrations (data not shown).
Discussion
The antiplatelet effects of aspirin were suppressed when
aspirin was added after ibuprofen, regardless of the con-
centration of ibuprofen. TXB2 level in platelet suspen-
sion in the ibuprofen plus aspirin group was higher than
that in the aspirin only group. Platelet COX-1 inhibition
by aspirin was considered to be decreased (Fig. 3a and
b). Besides, PK/PD analysis showed that taking aspirin
2 h before ibuprofen can avoid this interaction, whereas
taking ibuprofen 12 h before aspirin cannot avoid this
interaction [27]. The binding constant of ibuprofen to
COX-1 (2.48 μM−1.hr−1) is larger than that of aspirin
(0.027 μM−1.hr−1) [28], and the concentration of ibupro-
fen 12 h after taking the medication (about 2 μM) is
nearly equal to the half maximal inhibitory concentration
(IC50) of ibuprofen to COX-1 (3.0 – 4.8 μM) [29–31]. This
Fig. 2 Effect of aspirin (Asp) and aspirin after ibuprofen (Ibu→ Asp)
addition on platelet aggregation threshold index (PATI). Ibuprofen
concentration of (a): maximum concentration after taking ibuprofen
at a dose of 200 mg, (b): the concentration 12 h after taking
ibuprofen at a dose of 200 mg. (n = 6 for a, n = 5 for b; *P < 0.05
compared with the control; †P < 0.05 compared with the aspirin
only group; These values represent the mean ± SEM.)
Fig. 3 TXB2 concentration of aspirin (Asp) and aspirin after ibuprofen
(Ibu→ Asp) addition. Ibuprofen concentration of (a): maximum
concentration after taking ibuprofen at a dose of 200 mg, (b): the
concentration 12 h after taking ibuprofen at a dose of 200 mg.
(n = 6 for a, n = 5 for b; *P < 0.05 compared with the control;
†P < 0.05 compared with the aspirin only group; The line
indicates the mean value.)
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concentration seems to be enough to inhibit the antiplate-
let effects of aspirin. Regarding the usual once-daily low-
dose aspirin regimen, it is difficult to avoid the interaction
between aspirin and ibuprofen because the antiplatelet ef-
fects of aspirin are suppressed by ibuprofen even if aspirin
is taken 12 h after ibuprofen administration. It is possible
to avoid this interaction when the dosing interval from
ibuprofen to aspirin is 22 h (in other words, from aspirin
to ibuprofen is 2 h) in this once-daily regimen [3]; however,
it is a considerably limited condition. Thus, it is desirable to
avoid taking ibuprofen by patients on low-dose aspirin
therapy.
Many studies focused on the interaction between as-
pirin and ibuprofen because ibuprofen is generally pre-
scribed worldwide [6, 32]. However, since loxoprofen
sodium is frequently prescribed in Japan [9, 12], and its
price is low, loxoprofen sodium is likely to be involved
in the case of taking low-dose aspirin and NSAIDs con-
comitantly in Japan.
Loxoprofen sodium is metabolized into four isomers
of loxoprofen-trans-OH (loxoprofen-RSS, SRS, RSR, and
SRR) in the human body [33]. Only loxoprofen-SRS has
antipyretic, analgesic, and anti-inflammatory action, and
Fig. 4 Effect of aspirin (Asp) and aspirin after loxoprofen-trans-OH
(Lox→ Asp) addition on platelet aggregation threshold index (PATI).
Loxoprofen-trans-OH concentration of (a): maximum concentration
after taking loxoprofen at a dose of 60 mg, (b): the concentration
6 h after taking loxoprofen at a dose of 60 mg, (c): 12 h after taking
loxoprofen at a dose of 60 mg (n = 6 for a and b, n = 5 for c; *P < 0.05
compared with the control; †P < 0.05 compared with the aspirin only
group; These values represent the mean ± SEM.)
Fig. 5 TXB2 concentration of aspirin (Asp) and aspirin after
loxoprofen-trans-OH (Lox→ Asp) addition. Loxoprofen-trans-OH
concentration of (a): maximum concentration after taking loxoprofen
at a dose of 60 mg, (b): the concentration 6 h after taking loxoprofen
at a dose of 60 mg, (c): the concentration 12 h after taking loxoprofen
at a dose of 60 mg (n = 6 for a and b, n = 5 for c; *P < 0.05 compared
with the control; The line indicates the mean value.)
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inhibit platelet COX-1 [34]. Though the percentage of
the SRS-isomer in loxoprofen-trans-OH used in our
study was unclear, it was considered one quarter. The
antiplatelet effects of aspirin were suppressed in when
loxoprofen-trans-OH was added at Cmax, whereas it was
not suppressed when loxoprofen-trans-OH was added at
the assumed concentration after 6 h (Fig. 4a and b).
TXB2 level in platelet suspension of the loxoprofen-
trans-OH (Cmax) plus aspirin group tended to be higher
than that of the aspirin only group. All the subjects ex-
hibited the same tendency although no significant differ-
ence was shown (Fig. 5a). However, TXB2 was not high
at the assumed loxoprofen-trans-OH concentration after
6 h of taking loxoprofen dose (Fig. 5b). Therefore, the
antiplatelet effects of aspirin were affected by loxopro-
fen; however, taking aspirin 6 h after loxoprofen admin-
istration could avoid this interaction. The theoretical
concentrations of loxoprofen-SRS are about 0.85 μM
(Cmax) and 0.04 μM (after 6 h of taking loxoprofen). The
Cmax of loxoprofen-SRS after a single oral dose of loxo-
profen tablet (60 mg) was about 1.17 μM [33]. The IC50
of loxoprofen-SRS to platelet COX-1 was about 0.38 μM
[29]. Therefore, the Cmax of loxoprofen-trans-OH was
enough to inhibit platelet COX-1 although this inhib-
ition was reversible, whereas loxoprofen-trans-OH con-
centration after 6 h of taking loxoprofen might be too
low to inhibit COX-1. Therefore, when loxoprofen-
trans-OH was added at the Cmax, it competitively im-
peded COX-1 acetylation by aspirin when NSAIDs reach
the active site on platelet COX-1 earlier than aspirin
[3]. Considering the theoretical concentrations of
loxoprofen-SRS, platelet COX-1 was difficult to be
inhibited by loxoprofen-SRS 6 h or more after taking
loxoprofen, thus this interaction can be avoided. Lox-
oprofen is eliminated rapidly [20], so the effect of
loxoprofen on the antiplatelet effect of aspirin was
thought to decrease within 6 h of taking loxoprofen.
The theoretical concentration of loxoprofen-SRS 4 h
after dosing (approximately 0.14 μM) was lower than
its IC50 against platelet COX-1 (approximately
0.38 μM) [20, 29]. However, we considered that the
platelet COX-1 might have been partially inhibited be-
cause the ratio of its IC50 to the concentration was only
2.7, which might be the border line at which the inter-
action was observed or not. Therefore, a dosing interval of
6 h from when loxoprofen is administered to when aspirin
is administered was considered sufficient, but it is unclear
whether the dosing interval of 6 h is necessary or not. Fur-
ther studies are needed to clarify whether a dosing interval
from when loxoprofen is administered to when aspirin is
administered is possible to be reduced less than 6 h with
avoiding this interaction.
In this study, the concentration of each NSAID was
determined based on the clinical single dose. Ibuprofen
and loxoprofen can be taken three times a day. However,
ibuprofen and loxoprofen are eliminated rapidly; there-
fore, they do not accumulate in the body even when they
are taken continuously [35].
We studied NSAID interference with the antiplatelet
effects of aspirin via COX-1 inhibitory activity of
NSAIDs; however, it is necessary to consider the rate of
COX-1 irreversible inhibition by aspirin, because two
forms of aspirin tablets, uncoated and enteric-coated,
with different solubility are widely used in Japan. Aspirin
is metabolized to salicylic acid and its half-life in human
plasma is approximately 5–15 min [36]. Platelet COX-1
is rapidly acetylated by aspirin in the portal vein during
this metabolism period. This time zone was determined
based on the decline in serum TXB2 concentration. A
sudden decline in serum TXB2 concentration occurs 0
to 1 h after taking uncoated aspirin tablets [14, 37], and
it is of great importance that NSAIDs bind to COX-1
and impede its acetylation by aspirin within this one
hour. In other words, unless loxoprofen-SRS binding
time zone to COX-1 overlaps with the COX-1 acetyl-
ation time zone by aspirin, this interaction might be
avoided. Considering platelet COX-1 inhibition by
loxoprofen-SRS, if loxoprofen is not administered within
6 h before or 1 h after (total 7 h) taking aspirin, loxopro-
fen will not suppress the antiplatelet effects of uncoated
aspirin tablets (Fig. 6). On the other hand, a slow de-
crease in serum TXB2 concentration occurs 2 to 7 h
after taking enteric-coated aspirin tablets [14]. Thus, if
loxoprofen is not administered within 4 h before or 7 h
after (total 11 h) taking aspirin, loxoprofen will not
interfere with the antiplatelet effects (Fig. 6). Consider-
ing a lifestyle of getting up at 6:00, going to bed at 22:00
and taking aspirin at 7:00 or 19:00, the longest time
period in which the interaction can be avoided is
achieved by administration of aspirin uncoated tablets at
7:00, which results in a period of 14 h (from 8:00 to
22:00) during which the interaction can be avoidable.
Thus, uncoated aspirin tablets are useful to prevent this
interaction when NSAIDs are taken several times daily.
As a supplement, some studies reported that gastric tox-
icity from aspirin could be eliminated by the use of
enteric-coated tablets; however most of them were
short-time studies [38, 39]. Others reported that enteric-
coating might have little clinical benefits reducing
gastrointestinal bleeding or ulceration longitudinally
[40, 41]. Therefore, enteric-coated aspirin is consid-
ered to be not always useful to avoid gastric toxicity.
In contrast to ibuprofen and loxoprofen, celecoxib is
known as a selective COX-2 inhibitor. No reduction of
the antiplatelet effects of aspirin was observed with cele-
coxib [10]. There are several clinical trials that report
the interaction between low-dose aspirin and celecoxib
when uncoated aspirin tablets are used in some cases;
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however, there are no reports that is specified the use of
enteric-coated aspirin. Celecoxib IC50 to platelet COX-1
was 6.7–8.3 μM [30, 31], and the maximum plasma con-
centration of celecoxib after a single oral dose of 200 mg
is about 2.1 μM. Celecoxib is not considered to interfere
with the inhibition of platelet COX-1 by aspirin. Cele-
coxib was not investigated in our study; however, COX-1
inhibition by celecoxib is considered limited. It is sug-
gested that celecoxib does not suppress the antiplatelet
effects of aspirin, regardless of the kind of tablet coating.
These findings suggest that NSAIDs can influence the
antiplatelet effects of aspirin depending on the time of
taking both drugs and the coating of aspirin tablets. Sup-
pression of the antiplatelet effects may lead to inefficient
prevention of cardiovascular events. In fact, patients re-
ceiving aspirin plus ibuprofen showed an increased risk
of cardiovascular mortality compared with those who re-
ceived aspirin alone [42]. Both ibuprofen and loxoprofen
are used as both ethical and over the counter drugs in
Japan, thus pharmacists need to counsel the patients
about the time of taking NSAIDs, including nonpre-
scription drugs, with low-dose aspirin.
When low-dose aspirin and NSAIDs are co-
administered, several reports showed that ibuprofen
suppressed the antiplatelet effects of aspirin; however,
celecoxib did not [3, 10, 11]. In addition, loxoprofen
suppressed the antiplatelet effects when co-administered
with aspirin at the same time; however, this interaction is
avoidable [13]. Moreover, the extent to which this inter-
action is avoidable depends on the time of taking aspirin
and loxoprofen, and the coating of aspirin tablets. In this
model, the longest period (from 8:00 to 22:00) during
which the interference with the antiplatelet effects of as-
pirin is avoidable, is achieved when uncoated aspirin tab-
lets are administered at 7:00 in the morning.
Conclusions
It is desirable to avoid ibuprofen co-administration with
the usual once-daily low-dose aspirin therapy; however,
a 6-h interval between loxoprofen and aspirin could
avoid this potential interaction when loxoprofen is taken
before aspirin.
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